Phosphodiesterase: An Interface Connecting Cognitive Deficits to Neuropsychiatric and Neurodegenerative Diseases

Author(s): Zhen-Zhen Wang, Yi Zhang, Han-Ting Zhang, Yun-Feng Li

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 3 , 2015

Become EABM
Become Reviewer
Call for Editor


Phosphodiesterases (PDEs) are the only known enzymes to degrade intracellular cyclic AMP and/or cyclic GMP. The PDE superfamily consists of 11 families (PDE1– PDE11), each of which has 1 to 4 subtypes. Some of the subtypes may have multiple splice variants (e.g. PDE4D1–PDE4D11), leading to a total of more than 100 known proteins to date. Growing attention has been paid to the potential of PDEs as therapeutic targets for mood disorders and/or diseases affecting cognitive activity by controlling the rate of hydrolysis of the two aforementioned second messengers in recent years. The loss of cognitive functions is one of the major complaints most patients with CNS diseases face; it has an even more prominent negative impact on the quality of daily life. Cognitive dysfunction is usually a prognosis in patients suffering from neuropsychiatric and neurodegenerative diseases, including depression, schizophrenia, and Alzheimer’s disease. This review will focus on the contributions of PDEs to the interface between cognitive deficits and neuropsychiatric and neurodegenerative disorders. It is expected to make for the understanding and discovery that selective PDE inhibitors have the therapeutic potential for cognitive dysfunctions associated with neuropsychiatric and neurodegenerative disorders.

Keywords: Phosphodiesterase, cognitive deficit, neuropsychiatric disease, neurodegenerative diseases, cyclic AMP, cyclic GMP, PDE4 subtype, splice variant.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 26 August, 2014
Page: [303 - 316]
Pages: 14
DOI: 10.2174/1381612820666140826115559
Price: $65

Article Metrics

PDF: 79